drug

Dextroamphetamine

MeSH D003913
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by NYU Langone Health
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia
NCT03999190—Withdrawn
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
NCT02634684Phase 2Completed

KOLs & investigators

2
William Frankle
Neal R. Swerdlow, M.D., Ph.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
NYU Langone Health
company
trial
Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia
trial
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
PHASE2
trial
indication
Schizophrenia
indication
Mental Disorders
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
William Frankle
KOL score —
person
Neal R. Swerdlow, M.D., Ph.D.
KOL score —
person